Literature DB >> 34567938

Conversion surgery of Stage IV gastric cancer with peritoneal dissemination after nivolumab.

Yuji Toyota1, Kunio Okamoto2,3, Norimitsu Tanaka4, Hugh Shunsuke Colvin4, Yuta Takahashi4, Tomoki Inaba3.   

Abstract

A 69-year-old man was clinically diagnosed as stage IV gastric cancer with peritoneal dissemination. We performed systemic chemotherapy consisting of S-1 plus oxaliplatin as a first line, and ramucirumab plus nab-paclitaxel as a second line. However, CT and EGD revealed growth of the primary tumor and the lymph nodes along the lesser curvature and adjacent to the cardia. In addition, CT revealed ascites in the rectovesical pouch. Therefore, treatment was switched to nivolumab. After 3 treatment courses, CT revealed shrinkage of lymph nodes and disappearance of ascites. After 12 courses of nivolumab, however, EGD revealed growth of the tumors in the stomach with minor hemorrhage, prompting the consideration of gastrectomy. At the time of laparotomy, the peritoneal dissemination had completely disappeared, and peritoneal cytology was negative. Therefore, total gastrectomy with D2 and paraaortic lymphadenectomy was performed, after 21 months following the initial diagnosis. To our knowledge, there are no previous reports that have demonstrated the disappearance of peritoneal dissemination and ascites in response to nivolumab, resulting in curative gastrectomy. © The Japan Society of Clinical Oncology 2021.

Entities:  

Keywords:  Conversion surgery; Gastric cancer; Nivolumab

Year:  2021        PMID: 34567938      PMCID: PMC8421496          DOI: 10.1007/s13691-021-00503-0

Source DB:  PubMed          Journal:  Int Cancer Conf J        ISSN: 2192-3183


  13 in total

1.  Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial.

Authors:  Kohei Shitara; Mustafa Özgüroğlu; Yung-Jue Bang; Maria Di Bartolomeo; Mario Mandalà; Min-Hee Ryu; Lorenzo Fornaro; Tomasz Olesiński; Christian Caglevic; Hyun C Chung; Kei Muro; Eray Goekkurt; Wasat Mansoor; Raymond S McDermott; Einat Shacham-Shmueli; Xinqun Chen; Carlos Mayo; S Peter Kang; Atsushi Ohtsu; Charles S Fuchs
Journal:  Lancet       Date:  2018-06-04       Impact factor: 79.321

2.  Prevalence of Th17 and Treg cells in gastric cancer patients and its correlation with clinical parameters.

Authors:  Qiaoxia Li; Qingjing Li; Jinxia Chen; Yu Liu; Xuefeng Zhao; Bibo Tan; Jun Ai; Zhiping Zhang; Jingjing Song; Baoen Shan
Journal:  Oncol Rep       Date:  2013-06-27       Impact factor: 3.906

3.  [Successful Treatment of Gastric Cancer with Conversion Surgery after Nivolumab Treatment-A Case Report].

Authors:  Tadashi Shiraishi; Masayuki Kano; Haruhito Sakata; Kentaro Murakami; Takeshi Toyozumi; Nobufumi Sekino; Koichiro Okada; Toshiki Kamata; Takahiro Ryuzaki; Hisahiro Matsubara
Journal:  Gan To Kagaku Ryoho       Date:  2019-10

Review 4.  Cancer immunotherapy using checkpoint blockade.

Authors:  Antoni Ribas; Jedd D Wolchok
Journal:  Science       Date:  2018-03-22       Impact factor: 47.728

5.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.

Authors:  Hyuna Sung; Jacques Ferlay; Rebecca L Siegel; Mathieu Laversanne; Isabelle Soerjomataram; Ahmedin Jemal; Freddie Bray
Journal:  CA Cancer J Clin       Date:  2021-02-04       Impact factor: 508.702

6.  Multidisciplinary treatment for patients with stage IV gastric cancer: the role of conversion surgery following chemotherapy.

Authors:  Seung-Hoon Beom; Yoon Young Choi; Song-Ee Baek; Shuang-Xi Li; Joon Seok Lim; Taeil Son; Hyoung-Il Kim; Jae-Ho Cheong; Woo Jin Hyung; Seung Ho Choi; Minkyu Jung; Hyo Song Kim; Hei-Cheul Jeung; Hyun Cheol Chung; Sun Young Rha; Sung Hoon Noh
Journal:  BMC Cancer       Date:  2018-11-15       Impact factor: 4.430

7.  PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer.

Authors:  Takahiro Kamada; Yosuke Togashi; Christopher Tay; Danbee Ha; Akinori Sasaki; Yoshiaki Nakamura; Eiichi Sato; Shota Fukuoka; Yasuko Tada; Atsushi Tanaka; Hiromasa Morikawa; Akihito Kawazoe; Takahiro Kinoshita; Kohei Shitara; Shimon Sakaguchi; Hiroyoshi Nishikawa
Journal:  Proc Natl Acad Sci U S A       Date:  2019-04-26       Impact factor: 11.205

8.  Comprehensive molecular characterization of gastric adenocarcinoma.

Authors: 
Journal:  Nature       Date:  2014-07-23       Impact factor: 49.962

9.  Conversion surgery for stage IV gastric cancer with a complete pathological response to nivolumab: a case report.

Authors:  Ryu Matsumoto; Takaaki Arigami; Daisuke Matsushita; Keishi Okubo; Takako Tanaka; Shigehiro Yanagita; Ken Sasaki; Masahiro Noda; Yoshiaki Kita; Shinichiro Mori; Hiroshi Kurahara; Takao Ohtsuka
Journal:  World J Surg Oncol       Date:  2020-07-21       Impact factor: 2.754

10.  Japanese gastric cancer treatment guidelines 2018 (5th edition).

Authors: 
Journal:  Gastric Cancer       Date:  2020-02-14       Impact factor: 7.370

View more
  1 in total

1.  Conversion surgery for microsatellite instability-high gastric cancer with a complete pathological response to pembrolizumab: a case report.

Authors:  Yoshifumi Hidaka; Takaaki Arigami; Yusaku Osako; Ryosuke Desaki; Masahiro Hamanoue; Sonshin Takao; Mari Kirishima; Takao Ohtsuka
Journal:  World J Surg Oncol       Date:  2022-06-10       Impact factor: 3.253

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.